Fig. 3.
Fig. 3. cPLA2 expression in PBM from healthy control and AIDS subjects and after GM-CSF therapy of AIDS patients. Equal amounts (20 μg of protein) of crude cellular lysate from PBM were subjected to immunoblot analysis for 5-LO and FLAP as described in Materials and Methods. Top panel, a representative Western blot and lower panel, mean densitometric data. (A) cPLA2 expression in PBM from healthy control and HIV-infected subjects expressed as a percent of values obtained from healthy control subjects. (B) cPLA2 expression in PBM from HIV-infected subjects treated with GM-CSF therapy, as assessed by densitometry and expressed as a percent of values derived from day 1 PBM. n = 9, P = not significant (NS).

cPLA2 expression in PBM from healthy control and AIDS subjects and after GM-CSF therapy of AIDS patients. Equal amounts (20 μg of protein) of crude cellular lysate from PBM were subjected to immunoblot analysis for 5-LO and FLAP as described in Materials and Methods. Top panel, a representative Western blot and lower panel, mean densitometric data. (A) cPLA2 expression in PBM from healthy control and HIV-infected subjects expressed as a percent of values obtained from healthy control subjects. (B) cPLA2 expression in PBM from HIV-infected subjects treated with GM-CSF therapy, as assessed by densitometry and expressed as a percent of values derived from day 1 PBM. n = 9, P = not significant (NS).

Close Modal

or Create an Account

Close Modal
Close Modal